SCHEMBL492409

SCHEMBL492409

CCCCc1ccc(OCCCN2CCCCC2)cc1

nearest known ligand 0.83

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 18/20 0.83
TSHR P16473 1/20 0.68
ACHE P22303 1/20 0.68
RAD52 P43351 1/20 0.68
LTA4H P09960 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19043080 0.94 HRH3 (0.77) HRH3TSHRACHERAD52LTA4H
SCHEMBL876980 0.93 LTA4H (0.75) HRH3TSHRLTA4H
SCHEMBL491770 0.93 HRH3 (0.82) HRH3TSHRACHERAD52
SCHEMBL9035011 0.91 HRH3 (0.78) HRH3TSHRACHERAD52
SCHEMBL5858552 0.91 HRH3 (0.80) HRH3TSHRACHERAD52
SCHEMBL23804894 0.91 HRH3 (0.77) HRH3TSHRACHERAD52LTA4H
SCHEMBL13492993 0.90 LTA4H (0.76) HRH3TSHRLTA4H
SCHEMBL17636032 0.89 HRH3 (0.71) HRH3TSHRACHERAD52LTA4H
SCHEMBL5486360 0.89 HRH3 (0.77) HRH3TSHRACHERAD52
SCHEMBL12061373 0.88 HRH3 (0.90) HRH3ACHERAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106041-B2 Combination product comprising an antagonist or inverse agonist of histamine receptor H3 and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs BIOPROJET (FR) 2012-01-31 US disclosed
EP-1641461-B1 COMBINATION PRODUCT COMPRISING AN ANTAGONIST OR INVERSE AGONIST OF HISTAMINE RECEPTOR H<SB>3</SB> AND AN ANTIPSYCHOTIC OR ANTIDEPRESSANT AGENT, AND USE THEREOF FOR THE PREPARATION OF A MEDICAMENT THAT PREVENTS THE ADVERSE EFFECTS OF PSYCHOTROPIC DRUGS BIOPROJET SOC CIV (FR) 2010-09-29 EP disclosed
US-20060210624-A1 Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs BIOPROJET (FR) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060210624-A1 Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs HRH3, HRH4, HRH2 HRH3 1/4885TSHR 176/4885ACHE 626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.